医学
数据库
安全概况
药理学
不利影响
计算机科学
作者
Mimi L.K. Tang,Peiyan Liu,Lin-Zhe Du,Yuanyuan Li,Jinjin Chen,Yang Li
标识
DOI:10.1080/14740338.2024.2392011
摘要
Talazoparib was approved for the treatment of breast cancer. However, the safety of talazoparib in a large population sample over an extended period remained uncertain. The objective of this study is to offer guidance for the secure utilization of talazoparib in clinical settings. Methods: Four algorithms were used to quantify the signals of talazoparib associated adverse events(AEs), using data from the food and drug administration adverse event reporting system(FAERS) between fourth quater of 2018 and second quater of 2023.
科研通智能强力驱动
Strongly Powered by AbleSci AI